ALFA Finder| Management target | Revenue 100.0% FY27 |
|---|
| Revenue growth | 38% YoY revenue growth to 72.97 Cr in Q1 FY27. |
|---|---|
| Margins | EBITDA margin improved to 29%; 35%+ targeted via API integration. |
| Demand visibility | Strong, backed by 65+ contracts and 50+ international opportunities. |
| Management confidence | High, focused on scaling specialized oncology exports and API integration. |
Growth
Oncology grew 100%+, contributing 33 Cr. Export contribution remains low but is expected to scale 10x.
Outlook
Guided to double Oncology revenue this FY; aiming for 280-300 Cr Oncology revenue by FY28.
Risks
Low export contribution currently and reliance on long timeline marketing authorization approvals for growth.
Last quarter's promises, checked
Delivered
- Guided 40% growth for FY26 → delivered 42% (= BEAT)
- Guided 60% gross margins → delivered 60% (= BEAT)
- Guided 25-30% EBITDA margins → delivered 37% in Q4 (= BEAT)
Partly delivered
- Guided 300+ dossier registrations in 2 years → 130+ filed, 12 approved (= PARTIAL)
Missed
- Guided Q4 run rate near 38-40 Cr oncology → delivered 31.46 Cr (= MISS)
Earnings Call Transcript filed with NSE, NSE: SAKAR. Summary written with AI assistance from the document.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹1,083.70
- Market cap
- ₹2,411 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 56.2×Sector 43.8×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.